IP Library Granted Patent US 7,229,613
Granted Patent B2
US 7,229,613 · App. 10/125,700 · Granted Jun 12, 2007

Method for lowering serum glucose

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,229,613
App. No.
10/125,700
Granted
Jun 12, 2007
Kind
B2
Abstract

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

Claims (4)

1. A method for reducing serum glucose levels in a human diabetic patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof.

2. A method for reducing serum glucose levels in a human diabetic patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof, wherein said colesevelam or pharmaceutically acceptable salt thereof is the only active ingredient administered to the patient.

3. The method of claim 1 , wherein a pharmaceutically acceptable salt of colesevelam is administered to the patient.

4. The method of claim 2 , wherein a pharmaceutically acceptable salt of colesevelam is administered to the patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2006
From: DONOVAN, JOANNE M
To: GENZYME CORPORATION
Reel/Frame 017433/0561 →
MERGER Recorded May 5, 2003
From: GELTEX PHARMACEUTICALS, INC.
To: GENZYME CORPORATION
Reel/Frame 014026/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2002
From: BURKE, STEVEN K.
To: GELTEX PHARMACEUTICALS, INC.
Reel/Frame 013105/0159 →